Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines

PHASE2CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

May 20, 2019

Primary Completion Date

September 1, 2020

Study Completion Date

September 1, 2020

Conditions

Glabellar Frown Lines

Interventions

DRUG

MBA-P01 (Botulinum toxin A)

Intramuscular injection, dose varies by groups

DRUG

Placebo

Intramuscular injection

Trial Locations (1)

Maroubra MEdical Centre, Maroubra

All Listed Sponsors

lead

Medy-Tox

INDUSTRY

NCT04143815 - Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines | Biotech Hunter | Biotech Hunter